Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 42Observational 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 2Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Gene Expression Profiling 9Blood Specimen Collection 6Polymerase Chain Reaction 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 5Surveys and Questionnaires 3Sunitinib 3Reverse Transcriptase Polymerase Chain Reaction 3Flow Cytometry 3Biopsy 3Surgical Procedures, Operative 2Radiotherapy 2Radiosurgery 2Patient Reported Outcome Measures 2Observation 2Nivolumab 2Microarray Analysis 2Immunotherapy 2Genetic Testing 2Drug Therapy 2DNA Methylation 2Cytogenetic Analysis 2tremelimumab 1pembrolizumab 1durvalumab 1atezolizumab 1aldesleukin 1X-Rays 1Watchful Waiting 1Tomography, Optical Coherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Kidney Neoplasms × aldesleukin × Clear all
NCT00617799 2023-10-10

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

University of Nebraska

Completed
15 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡